Studies show that Non-Alcoholic Fatty Liver Disease (NAFLD) is prevalent among 9-53% of the general population. While these statistics are largely driven by a combination of environmental and genetic factors, experts at Amrita Hospital, Faridabad highlight that Indians have a heightened predisposition to insulin resistance,
Dr. Rajiv Lochan Lead ConsultantManipal Hospital Old Airport Road, Yeshwanthpur & Sarjapur Liver disease can be caused by numerous genetic and developmental problems with the liver which can lead to liver diseases. In children, biliary atresia, a condition where the bile ducts in the liver do
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) AstraZeneca Pharma India Ltd. (AstraZeneca India), a science-led biopharmaceutical company, announced it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for its cancer drug Tremelimumab Concentrate
Dr. Raghu DK Consultant Gastroenterologist and Hepatologist, Apollo Hospitals, Jubilee Hills. Non Alcoholic Fatty Liver Disease (NAFLD) is a condition characterised by the build up of fat (fatty infiltration) in the liver. NAFLD has become increasingly common in the recent times in India and the west as there
Dr Bharani Consultant Gastroenterologist and Hepatologist, Apollo Hospitals, Secunderabad The liver is the second largest & most important organ in the human body, which functions to remove all harmful chemicals like drugs and toxins, and helps in digestion, acts like a store house for vitamins, minerals and other
-An algorithm based testing for Fatty Liver Disease- ~First line diagnostic test for Non Alcoholic Fatty Liver Diseases~ SRL Diagnostics today announced the launch of ‘Fatty Liver Index’; a first line diagnostic test for Non Alcoholic Fatty Liver Disease. Fatty Liver Index (FLI) is an algorithm based
